Agilent Technologies (NYSE:A) Price Target Cut to $150.00 by Analysts at Barclays

Agilent Technologies (NYSE:A) had its target price reduced by Barclays from $165.00 to $150.00 in a report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other analysts have also weighed in on A. Weiss Ratings reissued a “hold (c+)” rating on shares of Agilent Technologies in a report on Monday, December 29th. Morgan Stanley initiated coverage on Agilent Technologies in a research note on Tuesday, December 2nd. They issued an “overweight” rating for the company. Evercore upgraded Agilent Technologies from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $155.00 to $160.00 in a research report on Monday, January 5th. Citigroup raised their price target on Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Finally, JPMorgan Chase & Co. boosted their price objective on Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $161.29.

Agilent Technologies Stock Performance

Shares of NYSE:A opened at $121.00 on Thursday. The business has a fifty day moving average of $134.99 and a 200-day moving average of $135.87. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $160.27. The firm has a market cap of $34.22 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by ($0.01). The company had revenue of $1.80 billion for the quarter, compared to analyst estimates of $1.81 billion. Agilent Technologies had a return on equity of 24.95% and a net margin of 18.26%.The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, equities research analysts predict that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Stockholders of record on Tuesday, March 31st will be given a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Tuesday, March 31st. Agilent Technologies’s payout ratio is currently 22.32%.

Institutional Investors Weigh In On Agilent Technologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Core Wealth Advisors LLC bought a new position in shares of Agilent Technologies in the 4th quarter valued at about $26,000. Board of the Pension Protection Fund acquired a new position in Agilent Technologies during the fourth quarter valued at approximately $27,000. Navalign LLC bought a new position in Agilent Technologies in the fourth quarter valued at approximately $27,000. MV Capital Management Inc. acquired a new position in shares of Agilent Technologies during the 4th quarter worth approximately $28,000. Finally, Capital A Wealth Management LLC raised its stake in shares of Agilent Technologies by 10,600.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 214 shares of the medical research company’s stock worth $25,000 after purchasing an additional 212 shares in the last quarter.

Key Stories Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Management set a FY‑26 revenue target of $7.3B–$7.5B and said it is expanding its “Ignite” operating system to drive margin improvement — a strategic signal that management expects revenue and margin expansion over the year. Agilent outlines $7.3B–$7.5B FY26 revenue target
• Positive Sentiment: Company-issued guidance: FY‑26 EPS range of 5.900–6.040 and Q2 EPS guidance roughly in-line with consensus, which provides a forward box for expectations and suggests management confidence despite a soft quarter. Agilent earnings/guidance details
• Neutral Sentiment: Top line growth remains positive — revenue rose about 7% YoY to ~$1.80B — but it narrowly missed some sell‑side estimates, leaving the print mixed from a growth standpoint. Agilent Q1 earnings/revenue recap
• Negative Sentiment: EPS missed consensus by $0.01 (reported $1.36 vs. ~$1.37 consensus) and revenue came in slightly below estimates; management cited a U.S. winter snowstorm that disrupted shipments and hurt margins — the immediate driver of the share decline. Agilent shares fall after Q1 earnings miss
• Negative Sentiment: Profitability and cash-flow signs were weak: operating profit and operating cash flow declined year-over-year, which raises near-term margin and free-cash-flow concerns for investors focused on quality of earnings. Q1 results: cash flow and profit weakness
• Negative Sentiment: Several brokers trimmed price targets (UBS, TD Cowen, Wells Fargo, Barclays) while largely maintaining buy/overweight ratings — a sign of reduced near‑term upside and caution among analysts despite longer‑term positive views. Analyst price target changes

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.